Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
REHOVOT, Israel, Feb. 27, 2017 -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences:
- Cowen and Company 37th Annual Health Care Conference taking place in Boston, Massachusetts from March 6 – 8, 2017. Dr. Lieberman’s presentation will take place on Monday, March 6 at 2:00pm ET.
- 29th Annual ROTH Conference taking place in Dana Point, California from March 12 – 15, 2017. Dr. Lieberman’s presentation will take place on Tuesday, March 14 at 9:00am PT, 12:00pm ET.
To access the live webcast of the presentation, please visit ir.neuroderm.com/. A replay will be available for a limited time following the presentation.
About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Rabin Science Park, Rehovot, Israel.
NeuroDerm Contact:
Oded S. Lieberman, PhD, CEO
[email protected]
Tel.: +972-8-946 2729;
Cell: +1-617-517 6077
U.S. Investor Contact:
David Carey
Lazar Partners Ltd.
[email protected]
+212-867-1768
